wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q26797297-4BA941E7-1F36-43AD-8474-307FB10D7F99
Q26797297-4BA941E7-1F36-43AD-8474-307FB10D7F99
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26797297-4BA941E7-1F36-43AD-8474-307FB10D7F99
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
P2860
Q26797297-4BA941E7-1F36-43AD-8474-307FB10D7F99
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26797297-4BA941E7-1F36-43AD-8474-307FB10D7F99
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
45cec40370afa4d4fef6cb9edb91ee4498a97c39
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.